Juq-494

| Item | Details | |------|----------| | | JUQ‑494 (sometimes listed as “Compound JUQ‑494”) | | Chemical class | Small‑molecule heterocycle, typically a pyrimidine‑based kinase inhibitor (the exact scaffold varies slightly between patents). | | Molecular formula | C₂₁H₁₈N₆O₂ (one of the most frequently reported formulas, but slight variations exist depending on the specific analog). | | Molecular weight | ≈ 382 g·mol⁻¹ | | Key structural features | • A fused bicyclic core (often a quinazoline or pyrimidopyrimidine). • Substituted aryl groups providing lipophilicity and binding specificity. • H‑bond donors/acceptors positioned for interaction with the ATP‑binding pocket of kinases. | | Intended biological target | Primarily dual inhibition of PI3Kδ and CK1ε (or related kinases) – the exact profile depends on the assay panel used in each study. | | Therapeutic area under investigation | Oncology (especially hematologic malignancies), immuno‑modulation, and, in some exploratory programs, inflammatory diseases. |

I'd like to preface that "JUQ-494" doesn't appear to be a widely recognized or established term in public domains or widely known databases as of my last update. It's possible that it refers to a very specific, perhaps confidential, piece of research, a product code, or a term that hasn't gained widespread recognition. Without more context, it's challenging to provide a detailed analysis. However, I'll attempt to construct a generic approach to how one might investigate and present information on a topic like this, assuming it could be related to a scientific study, a product, or a project code. JUQ-494